Doern G V
Department of Clinical Microbiology, University of Massachusetts Medical Center, Worcester 01655.
Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):75-7. doi: 10.1016/0732-8893(91)90092-t.
The in vitro activity of ceftibuten, a new orally administered cephalosporin, was assessed against clinical isolates of Haemophilus influenzae and Branhamella catarrhalis. The activity of ceftibuten was compared to that of ampicillin, amoxicillin-clavulanic acid, and three oral cephalosporins, cefaclor, cefuroxime, and cefixime. With the exception of rare beta-lactamase-negative ampicillin-resistant strains of H. influenzae, resistance to ceftibuten was not observed with any of the study isolates. Ceftibuten was more active than amoxicillin/clavulanic acid for beta-lactamase-positive and -negative strains of H. influenzae; it was less active than this combination for B. catarrhalis. Ceftibuten was essentially equivalent in activity to cefixime against both Haemophilus and Branhamella but more active than cefaclor and cefuroxime against these two organisms.
对一种新的口服头孢菌素——头孢布烯的体外活性进行了评估,以检测其对流感嗜血杆菌和卡他莫拉菌临床分离株的活性。将头孢布烯的活性与氨苄西林、阿莫西林-克拉维酸以及三种口服头孢菌素(头孢克洛、头孢呋辛和头孢克肟)的活性进行了比较。除了罕见的β-内酰胺酶阴性的耐氨苄西林流感嗜血杆菌菌株外,在任何研究分离株中均未观察到对头孢布烯的耐药性。对于β-内酰胺酶阳性和阴性的流感嗜血杆菌菌株,头孢布烯比阿莫西林/克拉维酸更具活性;对于卡他莫拉菌,其活性低于该组合。头孢布烯对嗜血杆菌属和卡他莫拉菌的活性基本上与头孢克肟相当,但对这两种菌的活性比头孢克洛和头孢呋辛更强。